Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects

N Tsuyama, K Sakamoto, S Sakata… - Journal of clinical and …, 2017 - jstage.jst.go.jp
Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a large-cell neoplasm
with anaplastic morphology immunostained by the Ki-1 antibody, which recognizes CD30. In …

When the good go bad: mutant NPM1 in acute myeloid leukemia

P Kunchala, S Kuravi, R Jensen, J McGuirk, R Balusu - Blood reviews, 2018 - Elsevier
Abstract Nucleophosmin 1 (NPM1) is a nucleolar phosphoprotein that performs diverse
biological functions including molecular chaperoning, ribosome biogenesis, DNA repair …

Legionella effector LnaB is a phosphoryl-AMPylase that impairs phosphosignalling

T Wang, X Song, J Tan, W Xian, X Zhou, M Yu, X Wang… - Nature, 2024 - nature.com
AMPylation is a post-translational modification in which AMP is added to the amino acid side
chains of proteins,. Here we show that, with ATP as the ligand and actin as the host activator …

A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders

T Velusamy, MJ Kiel… - Blood, The Journal …, 2014 - ashpublications.org
The spectrum of cutaneous CD30-positive lymphoproliferative disorders (LPDs) includes
lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma …

Unraveling the potential of ALK-targeted therapies in non-small cell lung cancer: comprehensive insights and future directions

H Parvaresh, G Roozitalab, F Golandam, P Behzadi… - Biomedicines, 2024 - mdpi.com
Background and Objective: This review comprehensively explores the intricate landscape of
anaplastic lymphoma kinase (ALK), focusing specifically on its pivotal role in non-small cell …

Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives

C Tomasello, C Baldessari, M Napolitano, G Orsi… - Critical reviews in …, 2018 - Elsevier
In the last few years, the development of targeted therapies for non-small cell lung cancer
(NSCLC) expressing oncogenic driver mutations (eg EGFR) has changed the clinical …

Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions

P Vanden Borre, AB Schrock, PM Anderson… - The …, 2017 - academic.oup.com
Background Thyroid carcinoma, which is rare in pediatric patients (age 0–18 years) but
more common in adolescent and young adult (AYA) patients (age 15–39 years), carries the …

PD-1/PD-L1 pathway: a therapeutic target in CD30+ large cell lymphomas

W Xie, LJ Medeiros, S Li, G Tang, G Fan, J Xu - Biomedicines, 2022 - mdpi.com
The programmed death-ligands, PD-L1 and PD-L2, reside on tumor cells and can bind with
programmed death-1 protein (PD-1) on T-cells, resulting in tumor immune escape. PD-1 …

Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?

TK Olsen, I Panagopoulos, TR Meling, F Micci… - Neuro …, 2015 - academic.oup.com
Background We have previously characterized 19 ependymal tumors using Giemsa banding
and high-resolution comparative genomic hybridization. The aim of this study was to analyze …

[HTML][HTML] Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma

C Mao, M Poimenidou, BT Craig - Cancers, 2024 - mdpi.com
Simple Summary Neuroblastoma (NBL) is the most common extracranial cancer in children.
High-risk NBL is characterized by bone marrow metastasis and MYCN oncogene …